Venetoclax Clinical Trials
222 recruitingDrug
Phase 2147Phase 182Phase 319Not Applicable11Phase 42Early Phase 12
Showing 1–20 of 222 trials
Recruiting
Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
CLLLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic+3 more
Merck Sharp & Dohme LLC735 enrolled55 locationsNCT05947851
Recruiting
Phase 1
CIML NK Cells With Venetoclax for AML
Acute Myeloid LeukemiaLeukemiaLeukemia, Myeloid+1 more
Dana-Farber Cancer Institute10 enrolled2 locationsNCT06152809
Recruiting
Phase 2
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
Core Binding Factor Acute Myeloid Leukemia
National Cancer Institute (NCI)162 enrolled29 locationsNCT06917911
Recruiting
Phase 2
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
T-cell Acute Lymphoblastic LeukemiaT-Cell Lymphoblastic Lymphoma
M.D. Anderson Cancer Center22 enrolled1 locationNCT06561074
Recruiting
Phase 3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
BeOne Medicines500 enrolled91 locationsNCT07277231
Recruiting
Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
National Cancer Institute (NCI)247 enrolled631 locationsNCT04269902
Recruiting
Phase 3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Chronic Lymphocytic LeukemiaCLL
BeOne Medicines250 enrolled124 locationsNCT06846671
Recruiting
Not Applicable
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China110 enrolled1 locationNCT07493161
Recruiting
Phase 1
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Seagen, a wholly owned subsidiary of Pfizer178 enrolled53 locationsNCT04227847
Recruiting
Phase 2
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
Mantle Cell Lymphoma (MCL)
The First Affiliated Hospital with Nanjing Medical University39 enrolled2 locationsNCT07719556
Recruiting
Phase 1Phase 2
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Mantle Cell LymphomaBlastoid Variant Mantle Cell LymphomaPleomorphic Variant Mantle Cell Lymphoma
City of Hope Medical Center50 enrolled3 locationsNCT05861050
Recruiting
Phase 1
MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Multiple Myeloma
Mayo Clinic100 enrolled1 locationNCT06042725
Recruiting
Phase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled348 locationsNCT05564390
Recruiting
Phase 2
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Recurrent Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia Variant
National Cancer Institute (NCI)20 enrolled21 locationsNCT06311227
Recruiting
Phase 1Phase 2
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaLymphoma+1 more
National Cancer Institute (NCI)155 enrolled1 locationNCT03223610
Recruiting
Phase 2
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular Lymphoma+3 more
Chinese PLA General Hospital30 enrolled1 locationNCT06471738
Recruiting
Phase 2Phase 3
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
Acute Myeloid Leukemia (AML)
University Hospital, Angers3,100 enrolled56 locationsNCT02416388
Recruiting
Phase 2
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center45 enrolled7 locationsNCT07392242
Recruiting
Phase 1Phase 2
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
T-cell Prolymphocytic LeukemiaCutaneous T-Cell Lymphoma Refractory
Jonsson Comprehensive Cancer Center12 enrolled1 locationNCT06810778
Recruiting
Phase 1
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Acute Myeloid Leukemia
M.D. Anderson Cancer Center125 enrolled1 locationNCT05010772